The pandemic has been a game-changer for the pharmaceutical industry, sending the seemingly inexorable globalisation trends into reverse, with Big Pharma increasingly seeking more domestic supply chain options. Here, Karen Winterhalter of Onyx Health shares her expert insights on the impact of this emerging trend on the industry.
The recent economic disruption caused by the COVID-19 pandemic sent shockwaves across the pharmaceutical industry, disrupting its supply chains, delaying production and creating a shortage of vital medicines.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Can’t attend live? No worries – register to receive the recording post-event.
It is estimated that 43 percent of acute care medicines such as antibiotics, blood thinners and sedatives ran in low supply during the peak of the crisis.1
One of the key areas affected by the disruption was the active pharmaceutical ingredient (API) market.2 APIs are the biologically active component in tablets or drug capsules used in everyday medications like paracetamol.
Like so many industries, the sector has seen a trend of outsourcing API manufacturing activity away from Europe and North America toward China to cut production costs due to the rise of globalisation.3
The economic forces of globalisation have reshaped the world economy; accelerating global growth, raising living standards in developing countries and reducing income inequalities between developed and developing countries. However, this has come at a cost for those left behind. It has widened income inequalities within developed countries, hollowing out the West’s pharmaceutical manufacturing capabilities and exposing them to sudden shocks in the global economy.
The pandemic has starkly exposed the fragility of the global supply chain and over-reliance on China as a manufacturing location.
The fragility of global supply chains
When the COVID-19 crisis first started in China’s Wuhan province in January 2020, the Chinese Government imposed nationwide restrictions to tackle the virus’s rapid spread. This quickly exposed the global pharmaceutical industry’s over-reliance on China to produce APIs. It is estimated that 44 companies were left non-operational during the pandemic due to lockdown restrictions in China. As a result, access to vital APIs and medicines we were drastically restricted.1
The relentless rise of outsourcing that has taken place over the past decades has led to a dangerous structural imbalance in the global pharmaceutical market. It is estimated that 80 percent of APIs for essential medicines across key therapeutic areas in the US had no domestic manufacturing source4 and this has serious worldwide health implications. APIs are key components in the medications used to treat chronic underlying health conditions such as cardiovascular disease, strokes, heart attacks, diabetes and more. The shortages were so severe at the peak of the pandemic that the UK’s National Health Service (NHS) publicly called on the UK Government to bring more pharmaceutical manufacturing back to the UK to future proof medicine supply chains.5
The scale of the global problem has been recognised by President Joe Biden, who has made onshoring a key focus of his recently passed Infrastructure Bill and issued an Executive Order to secure and strengthen America’s supply chains, including the pharmaceutical industry.6
The rise of China as a major player on the world stage has led to it becoming a dominant force in the global pharmaceutical industry.
The sheer size and scale of its production capacity, as well as lower operating costs, mean that China’s APIs have become the most widely used worldwide, surpassing previous market leaders like India, who now receive 70 percent of their API supply from China.7
China’s economic ascendancy meant that Western manufacturers in Europe and North America could no longer compete. They largely outsourced their traditional API manufacturing capabilities to cut costs and remain commercially competitive.
APIs are an asset of strategic importance to the global pharmaceutical industry. There is a need to establish a diverse range of production locations to create a more stable and efficient market”
However, it is clear that outsourcing itself comes at a cost. When the production of APIs vital for the global medicine supply is dominated by one country, the Western world is in a precarious position.
Research by McKinsey shows that supply chains in the pharmaceutical industry are more global than in other sectors and there is a tendency to source certain materials from a particular region. For instance, 86 percent of the streptomycin in North America and 96 percent of the chloramphenicol in the European Union comes from China.8
APIs are an asset of strategic importance to the global pharmaceutical industry. There is a need to establish a diverse range of production locations to create a more stable and efficient market.
The industry is increasingly looking at more production options in their local region to rectify this imbalance. The UK’s Life Sciences Industrial Strategy has set an ambition to attract ten large and ten smaller manufacturing facilities to the UK, through the onshoring of manufacturing.9 Whilst this may be more expensive, it could well be a price worth paying for greater stability and security of supply.
Onshoring is the new outsourcing
The global economic disruption created by the COVID-19 crisis has led to pharmaceutical companies looking to reduce their reliance on Chinese suppliers and become more API independent.
Diversifying supply chain materials is an option that pharma companies could pursue to reduce their exposure through onshoring. McKinsey estimates that 38 to 60 percent of the international pharma trade, worth $236 billion to $377 billion in 2018, could be considered for onshoring.8
There has been a growing clamour for indigenous API and intermediary production to create more secure supply chains and lay stronger structural foundations.
A striking example is the Indian Government setting aside $1.3 billion to invest in domestic API production, shifting its pharmaceutical industry away from its reliance on Chinese APIs.7 India hopes the investment will enable it to reclaim some of the market share it previously lost to China and shore up its domestic supply to safeguard against a future crisis.
The European Commission (EC) has set out its vision for the future of supply chains in its EU Pharmaceutical Strategy, which includes initiatives to lead the charge on reshoring pharmaceutical production10. It includes a specific commitment to “strengthen the resilience of pharmaceutical supply chains and ensure the security of supply of medicines, without compromising the affordability of medicines”, which will take place across EU member countries.9
A recent example of this is the French pharmaceutical giant Sanofi announcing plans to launch a spin-out API European manufacturer.11 It will combine Sanofi’s API commercial and development activities with six production sites across Europe, securing domestic supply capacity.11
We must remember that diversifying supply chains is expensive for companies and the cost of reconfiguring them will either fall on consumers or governments. The UK’s Vaccine Taskforce is currently undertaking work to build and strengthen the UK’s vaccine supply chain by focusing on increasing domestic supply capabilities and engaging with pharmaceutical companies to invest in domestic production.12 However, it remains to be seen who will pick up the bill.
One of the fascinating economic consequences created by the present crisis has been to send the seemingly inexorable trends of globalisation into reverse, highlighting the need for an indigenous API strategy. Locally sourced API production will likely become an increasingly important part of Government policy and pharmaceutical companies’ commercial strategy. Tony Blair once famously said globalisation is a fact, not a choice; however, the reality in a post-COVID-19 world may be more complex.13 Whilst globalisation may remain a fact of economic life; companies may increasingly choose to onshore their manufacturing capabilities to increase their resilience to global economic headwinds.
About the author
Karen Winterhalter, Managing Director of Onyx Health, founded the company in 2009 when she returned to her native North East to set up her own communications agency. She has over 30 years of experience in pharmaceutical communications, having previously been European Director at Weber Shandwick and EMEA Managing Director for Burson Marsteller for their healthcare divisions.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.